Craft Health 3D Printer Passes First Peptide Test With PharmaTher

PharmaTher Holdings is running Craft Health's CraftMake printer through its first real peptide test. The goal is simple: replace manual compounding with a repeatable, GMP-compatible process that lets pharmacists personalize doses instead of forcing every patient into a fixed-dose tablet.

No Heat, No UV, No Degradation

CraftMake uses semi-solid paste extrusion at room temperature. That detail matters for peptides. Heat and UV light break down sensitive active ingredients, so traditional tablet presses and some resin processes are off the table. CraftMake avoids both by design. The printer can also produce multi-material, pill-in-pill structures, which means a single dose could release ingredients at different times or combine multiple compounds in one unit.

The GMP-ready version, CraftMake Production Plus, runs in an enclosed environment with dual printheads. Craft Health claims roughly plus-or-minus one percent dosing accuracy and repeatability above ninety-nine percent. Those numbers are not yet independently verified, but they set the benchmark for what the companies hope to demonstrate.

Why Fixed Doses Are a Compromise

Standardized tablets suit the average patient. They suit manufacturing even better. Once you commit to a dose, every patient gets the same amount regardless of weight, metabolism, or tolerance. Adjusting that dose usually means a pharmacist mixing something by hand. That is not a scalable system.

3D printing changes the economics. If the printer can produce a patient-specific dose with the same effort it takes to print a standard one, then personalization becomes a manufacturing step rather than a special exception. Craft Health and PharmaTher are not the only companies chasing this. CurifyLabs sells GMP pharmaceutical inks that let hospitals print tailored medicines on site. Max Planck and UC Davis researchers demonstrated shape-based release profiles using 3D printed pill geometries.

What Happens Next

The current agreement is an evaluation, not a manufacturing contract. PharmaTher and Craft Health will test formulations, dosage designs, and release profiles for six target peptides. If the data hold up, the next step could place CraftMake printers inside Section 503A compounding pharmacies, with PharmaTher supplying peptide strategy and prescriber relationships, and Craft Health supplying hardware, software, and formulation science.

No one expects 3D printed personalized peptides to replace mass-market drugs overnight. But the gap between a fixed dose and a personalized one has always been a manufacturing problem, not a clinical one. Printing, not pressing, is starting to close that gap.